Trials
3 active
11 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “300 mg BV100 nfused over 2 hours every 12 hours (q12h).Treatment for 7 days up to 14 days if clinically indicated.”In the company’s words, NCT07326540 on ClinicalTrials.gov
- Tested for
- Hospital Acquired Bacterial Pneumonia (HABP) (2 trials), Ventilator Associated Bacterial Pneumonia (VABP) (2 trials), Colistin Resistanrt ABC, Acinetobacter Baumannii-calcoaceticus Complex, Blood Stream Infection, Meningitis, Bacterial, Ventriculitis, Infectious
- Main trialPhase 3
- “This is a two-part study, with Part A being the randomized, controlled portion of the study in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) suspected or confirmed to be due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). Part B is the single-group portion of the study and includes patients with HABP or VABP with CRABC infections that are resistant to or have failed colistin/polymyxin B treatment.”In the company’s words, NCT07326540 on ClinicalTrials.gov
- Other names
- Rifabutin for Infusion
Other drugs for Hospital Acquired Bacterial Pneumonia (HABP)
- Group ACYW135 Meningococcal Conjugate VaccineSinovac Biotech Co., Ltd · Phase 3
- MenABCWY vaccineGSK · Phase 2
- DTcP-Hib-MCV4CanSino Biologics Inc. · Phase 1
- ACYW135XSinovac Life Sciences Co., Ltd. · Phase 1
- Batch 1 ofCanSino Biologics Inc. · Marketed (Phase 4 trial)
- RMenBGSK · Marketed (Phase 4 trial)
Coming up2
- 30 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2027 | Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex | |
| Phase 2Not yet recruiting | Mar 2028 | Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex | |
| Phase 1Recruiting | 30 Sep 2026 | A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers | |
| Phase 2Completed | 1 Nov 2024 | PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB | |
| Phase 1Completed | 12 Dec 2021 | Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects | |
| Phase 1Completed | 8 Apr 2022 | Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects | |
| Phase 1Completed | 30 May 2022 | Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment | |
| Phase 1Completed | 31 Jul 2023 | A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants | |
| Phase 1Completed | 30 Sep 2023 | To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100 | |
| Phase 1Completed | 30 Jul 2024 | A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment | |
| Phase 1Completed | 30 Oct 2024 | Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026